Press Releases

 Sign up for email alerts here

 

Date Title and Summary Additional Formats
Toggle Summary Genocea Reports Fourth Quarter and Year-End 2016 Financial Results
- Positive Phase 2b clinical data confirm attractive profile for GEN-003; expected to start Phase 3 program in 4Q 2017 - - Neoantigen cancer vaccine program on track to file first IND by end of 2017 - - Conference call at 9am ET today - CAMBRIDGE, Mass. , Feb.
View HTML
Toggle Summary Genocea to Host Fourth Quarter and Year End 2016 Financial Results Conference Call & Webcast on February 16, 2017
CAMBRIDGE, Mass. , Feb. 09, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, February 16, 2017 at 9:00 a.m.
View HTML
Toggle Summary Genocea Announces Positive 6-Month Results from GEN-003 Phase 2b Clinical Trial
- Trial meets statistical significance vs. placebo for multiple clinical endpoints through six months - - End of Phase 2 meeting with FDA expected in Q1 2017 - - Phase 3 launch expected in Q4 2017 - - GEN-003 has potential to be first new treatment for genital herpes infections in more than 20
View HTML
Toggle Summary Genocea R&D Day Highlighted Lead Program, GEN-003, for the Treatment of Genital Herpes and Introduced Immuno-Oncology Programs & Strategy
- GEN-003 Phase 2b placebo-controlled clinical efficacy data six months after dosing expected in January 2017 - - Announced new research collaborations with Checkmate Pharmaceuticals in advanced melanoma and US Oncology Research across multiple cancers - - Neoantigen cancer vaccine IND expected in
View HTML
Toggle Summary Genocea Announces Research Collaboration with Checkmate Pharmaceuticals in Advanced Melanoma
- Genocea's ATLAS technology to profile the T cell responses of patients enrolled in ongoing Phase 1b CMP-001/pembrolizumab clinical trial against library of common melanoma antigens - - Collaboration aims to identify antigens associated with therapeutic T cell responses - CAMBRIDGE, Mass. , Dec.
View HTML
Toggle Summary Genocea to Host Virtual R&D Day on December 14th, 2016
CAMBRIDGE, Mass. , Dec. 08, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, will host a virtual Research and Development (R&D) Day for analysts, investors and media on Wednesday, December 14,
View HTML
Toggle Summary Genocea's Proprietary ATLAS™ Technology Identifies Unique Candidate Antigens for Potential Personalized Cancer Vaccines
- ATLAS discovers neoantigens, through functional T cell responses, which were not identified by predictive algorithms - - Majority of antigens predicted by algorithms not biologically relevant in ATLAS assays - - Data to be presented at 2016 SITC Annual Meeting - CAMBRIDGE, Mass. , Nov.
View HTML
Toggle Summary Genocea to Present at Two Upcoming November Conferences
CAMBRIDGE, Mass. , Nov. 09, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at two upcoming investor conferences in November:
View HTML
Toggle Summary Genocea Reports Third Quarter 2016 Financial Results
- Positive Phase 2b results recently reported and d ose s elected for  GEN-003 Phase 3 program expected to i nitiate in 2H 2017 - - Conference Call at 9am ET today - CAMBRIDGE, Mass. , Nov. 03, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a company developing T cell-directed
View HTML
Toggle Summary Genocea Presents New 12 month Data on Genital Herpes Immunotherapy GEN-003 at IDWeek 2016
- Increase in CD4 + polyfunctional T cells indicates GEN-003 is stimulating a multi-faceted T cell immune response to genital herpes - - GEN-003 elicited strong antibody responses at 12 months post-dosing - CAMBRIDGE, Mass. , Oct. 28, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences ,
View HTML
Toggle Summary Genocea to Host Third Quarter 2016 Financial Results Conference Call & Webcast on November 3, 2016
CAMBRIDGE, Mass. , Oct. 27, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, November 3, 2016 at 9:00 a.m.
View HTML
Toggle Summary Genocea's Genital Herpes Immunotherapy GEN-003 Demonstrates Significant Reduction of Viral Shedding in Phase 2b Clinical Trial
- Trial achieves primary endpoint - - Dose confirmed for subsequent trials -   - Phase 3 expected to start in 2H 2017 - - Company to host conference call at 9 a.m. ET today - CAMBRIDGE, Mass. , Sept. 29, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company
View HTML
Toggle Summary Genocea Congratulates Jessica Baker Flechtner, Ph.D. for Recognition on 2016's 40 Women To Watch Over 40 List
Genocea Chief Scientific Officer honored for innovation in development of novel immunotherapies
View HTML
Toggle Summary Genocea Reports Second Quarter 2016 Financial Results
- GEN-003 Phase 2b Viral Shedding Data Expected in September 2016 -
View HTML
Toggle Summary Genocea to Host Second Quarter 2016 Financial Results Conference Call & Webcast on August 4, 2016
CAMBRIDGE, Mass. , July 28, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, August 4, 2016 at 9:00 a.m.
View HTML